Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.

ABSTRACT:

Objective

Cotadutide, a dual GLP-1 and glucagon receptor agonist, is under development for nonalcoholic steatohepatitis (NASH) and chronic kidney disease with type 2 diabetes. The effects of cotadutide on hepatic and metabolic parameters were evaluated in participants with overweight/obesity and type 2 diabetes.

Research design and methods

In this phase 2b study, 834 adults with BMI ≥25 kg/m² and type 2 diabetes inadequately controlled with metformin (glycated hemoglobin A_1c [HbA_1c] of 7.0%-10.5% [53-91 mmol/mol]) were randomized to double-blind cotadutide 100 μg (n = 100), 200 μg (n = 256), or 300 μg (n = 256); placebo (n = 110); or open-label liraglutide 1.8 mg (n = 110)-all administered subcutaneously. Co

SUBMITTER: Nahra R 

PROVIDER: S-EPMC8247525 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature